Poland
· Delayed Price · Currency is PLN Ryvu Therapeutics Statistics
Total Valuation
Ryvu Therapeutics has a market cap or net worth of PLN 1.21 billion. The enterprise value is 1.01 billion.
| Market Cap | 1.21B |
| Enterprise Value | 1.01B |
Important Dates
The last earnings date was Wednesday, September 11, 2024.
| Earnings Date | Sep 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ryvu Therapeutics has 23.12 million shares outstanding. The number of shares has increased by 12.71% in one year.
| Shares Outstanding | 23.12M |
| Shares Change (YoY) | +12.71% |
| Shares Change (QoQ) | -6.02% |
| Owned by Insiders (%) | 23.81% |
| Owned by Institutions (%) | 43.77% |
| Float | 15.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.65 |
| PB Ratio | 5.88 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.58 |
| EV / Sales | 12.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.98 |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 29.69.
| Current Ratio | 3.32 |
| Quick Ratio | 3.17 |
| Debt / Equity | 29.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | -471.20 |
Financial Efficiency
Return on equity (ROE) is -37.68% and return on invested capital (ROIC) is -22.62%.
| Return on Equity (ROE) | -37.68% |
| Return on Assets (ROA) | -15.79% |
| Return on Capital (ROIC) | -22.62% |
| Revenue Per Employee | 305,137 |
| Profits Per Employee | -354,911 |
| Employee Count | 270 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 7.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.94% in the last 52 weeks. The beta is 0.59, so Ryvu Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -19.94% |
| 50-Day Moving Average | 52.58 |
| 200-Day Moving Average | 54.49 |
| Relative Strength Index (RSI) | 43.54 |
| Average Volume (20 Days) | 5,447 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ryvu Therapeutics had revenue of PLN 82.39 million and -95.83 million in losses. Loss per share was -4.14.
| Revenue | 82.39M |
| Gross Profit | 65.60M |
| Operating Income | -105.08M |
| Pretax Income | -95.70M |
| Net Income | -95.83M |
| EBITDA | -95.13M |
| EBIT | -105.08M |
| Loss Per Share | -4.14 |
Balance Sheet
The company has 254.20 million in cash and 60.98 million in debt, giving a net cash position of 193.22 million or 8.36 per share.
| Cash & Cash Equivalents | 254.20M |
| Total Debt | 60.98M |
| Net Cash | 193.22M |
| Net Cash Per Share | 8.36 |
| Equity (Book Value) | 205.41M |
| Book Value Per Share | 8.88 |
| Working Capital | 207.30M |
Cash Flow
In the last 12 months, operating cash flow was -91.94 million and capital expenditures -9.59 million, giving a free cash flow of -101.53 million.
| Operating Cash Flow | -91.94M |
| Capital Expenditures | -9.59M |
| Free Cash Flow | -101.53M |
| FCF Per Share | -4.39 |
Margins
Gross margin is 79.63%, with operating and profit margins of -127.54% and -116.31%.
| Gross Margin | 79.63% |
| Operating Margin | -127.54% |
| Pretax Margin | -116.16% |
| Profit Margin | -116.31% |
| EBITDA Margin | -115.46% |
| EBIT Margin | -127.54% |
| FCF Margin | -123.24% |
Dividends & Yields
Ryvu Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.71% |
| Shareholder Yield | -12.71% |
| Earnings Yield | -7.94% |
| FCF Yield | -8.41% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ryvu Therapeutics has an Altman Z-Score of 3.79.
| Altman Z-Score | 3.79 |
| Piotroski F-Score | n/a |